U1 News
  • Home
  • World
  • U.S.
  • Business
  • Technology
  • Science
  • Entertainment
  • Sport
  • Health
Global News

Israel targets Hezbollah commander in Beirut strike after deadly Golan Heights attack

July 30, 2024

Taylor Swift speaks out after Southport mass stabbing at dance class

July 30, 2024

3 girls killed in stabbing at Taylor Swift-themed UK dance class. 7 people still critically wounded

July 30, 2024
Facebook Twitter Instagram
Trending
  • America’s 10 priciest prescription medications by cost and by volume
  • FDA head raises alarm on ‘gas station heroin’ impact on youth
  • New AI tool analyzes face photos to predict health outcomes
  • Worst cities for allergies revealed, along with tips to manage symptoms
  • FDA approves first at-home HPV test to screen for cervical cancer
  • Brain stimulation technology improves Parkinson’s treatment for music conductor
  • Left-handedness linked to autism, schizophrenia in major neurological study
  • Heart health unexpectedly affected by shingles vaccine
Tuesday, May 13
U1 News
  • Home
  • World

    Israel targets Hezbollah commander in Beirut strike after deadly Golan Heights attack

    July 30, 2024

    Taylor Swift speaks out after Southport mass stabbing at dance class

    July 30, 2024

    3 girls killed in stabbing at Taylor Swift-themed UK dance class. 7 people still critically wounded

    July 30, 2024

    Kerala, India, hit by landslides, killing at least 99

    July 30, 2024

    Taylor Swift ‘in shock’ after horrific UK stabbing, as police say 3rd child dies

    July 30, 2024
  • U.S.

    Biden criticises ‘extreme’ Supreme Court in push for reform

    July 30, 2024

    FBI details shooter’s search history before Trump assassination attempt

    July 30, 2024

    Reps. Mike Kelly, Jason Crow to lead task force on Trump rally shooting

    July 29, 2024

    Biden to call for major Supreme Court reforms, including term limits, at Civil Rights Act event Monday

    July 29, 2024

    Sonya Massey’s death revives pain for Breonna Taylor, Floyd activists

    July 29, 2024
  • Business

    AMD stock jumps on earnings beat driven by AI chip sales

    July 30, 2024

    Amazon is responsible for dangerous products sold on its site, federal agency rules

    July 30, 2024

    Microsoft investigating new outages of services after global CrowdStrike chaos

    July 30, 2024

    S&P 500, Nasdaq Tumble as Chip Stocks Slide Ahead of Big Tech Earnings

    July 30, 2024

    American consumers feeling more confident in July as expectations of future improve

    July 30, 2024
  • Technology

    Apple says Safari protects your privacy. We fact checked those claims.

    July 30, 2024

    GameStop Dunks On Xbox 360 Store Closing And Gets Savaged

    July 30, 2024

    Logitech has an idea for a “forever mouse” that requires a subscription

    July 30, 2024

    Friend: a new digital companion for the AI age

    July 30, 2024

    London Sports Mod Community Devolves Into War

    July 30, 2024
  • Science

    NASA’s Lunar Gateway has a big visiting vehicles problem

    August 1, 2024

    Boeing’s Cursed ISS Mission May Finally Make It Back to Earth

    July 30, 2024

    Should you floss before or after you brush your teeth?

    July 30, 2024

    Ancient swimming sea bug ‘taco’ had mandibles, new fossils show

    July 30, 2024

    NASA’s DART asteroid impact mission revealed ages of twin space rock targets (images)

    July 30, 2024
  • Entertainment

    Richard Gadd Backs Netflix to Get ‘Baby Reindeer’ Lawsuit Dismissed

    July 30, 2024

    Batman: Caped Crusader review: a pulpy throwback to DC’s Golden Age

    July 30, 2024

    Channing Tatum Praises Ryan Reynolds For Taking Gamble On Gambit

    July 30, 2024

    ‘Star Wars Outlaws’ somehow made me fall in love with Star Wars again

    July 30, 2024

    Great Scott and O’Brien’s Pub find new life in Allston

    July 30, 2024
  • Sport

    How Snoop Dogg became a fixture of the Paris Olympics

    July 30, 2024

    Team USA’s Coco Gauff exits Olympics singles tournament with a third-round loss : NPR

    July 30, 2024

    French police investigating abuse targeting Olympic opening ceremony DJ over ‘Last Supper’ scene

    July 30, 2024

    French DJ Takes Legal Action

    July 30, 2024

    Why BYU’s Jimmer Fredette is at the 2024 Paris Olympics

    July 30, 2024
  • Health

    America’s 10 priciest prescription medications by cost and by volume

    May 13, 2025

    FDA head raises alarm on ‘gas station heroin’ impact on youth

    May 12, 2025

    New AI tool analyzes face photos to predict health outcomes

    May 12, 2025

    Worst cities for allergies revealed, along with tips to manage symptoms

    May 11, 2025

    FDA approves first at-home HPV test to screen for cervical cancer

    May 10, 2025
U1 News
Home»Health»Antioxidants Slow Vision Loss in Late-Stage Dry AMD
Health

Antioxidants Slow Vision Loss in Late-Stage Dry AMD

u1news-staffBy u1news-staffJuly 17, 2024No Comments6 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Dry Amd Supplement Vision Neurosicence.jpg
Share
Facebook Twitter LinkedIn Pinterest Email

summary: Researchers have found that taking a daily antioxidant supplement slows the progression of late-stage dry age-related macular degeneration (AMD). The supplement helps preserve central vision by slowing the expansion of areas of geographic atrophy in the retina. This finding supports the use of AREDS2 supplementation for patients with late-stage dry AMD.

Key Facts:

  1. Benefits of the supplement: AREDS2 supplement slows the spread of geographic atrophy by 55%.
  2. Research details: The analysis included 1,209 eyes from the AREDS and AREDS2 trials.
  3. Preserving Vision: Antioxidants help preserve central vision in late-stage dry AMD.

sauce: NIH (National Institutes of Health)

In a new data analysis, researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals may slow the progression of late-stage dry age-related macular degeneration (AMD) and help patients with the end-stage disease preserve central vision.

The researchers examined original retinal scans from participants in the Age-Related Eye Disease Studies (AREDS and AREDS2) and found that in patients with late-stage dry AMD, taking antioxidant supplements slowed the expansion of the area of ​​geographic atrophy toward the foveal region of the retina.

“These findings support the continued use of AREDS2 supplementation in patients with late-stage dry AMD.” Credit: Neuroscience News

The study was published in the journal Ophthalmology.

“We have known for some time that AREDS2 supplementation can help slow the progression of intermediate to late AMD, and our analysis shows that taking AREDS2 supplementation can also slow disease progression in patients with late-stage dry AMD,” said Tiernan Keenan, M.D., Ph.D., of the NIH’s National Eye Institute (NEI) and lead author of the study.

“These findings support the continued use of AREDS2 supplements by patients with late-stage dry AMD.”

In the new analysis, the researchers looked at the original retinal scans of participants in the AREDS (318 participants, 392 eyes) and AREDS2 (891 participants, 1,210 eyes) who developed dry AMD and calculated the location and growth of areas of geographic atrophy.

For people with geographic atrophy in the central field, the supplements had little effect, but for the majority of people with geographic atrophy far from the fovea, the supplements slowed the rate of growth of atrophy toward the fovea by about 55% over an average of three years.

In early and intermediate AMD, small yellow deposits of fatty proteins called drusen form on the light-sensing retina at the back of the eye. As the disease progresses to later stages, blood vessels may become leaky (“wet” AMD) and some of the light-sensing cells in the retina may be lost (“dry” AMD). The geographic atrophy in these areas slowly increases over time, causing a gradual loss of central vision.

The original AREDS trial found that a supplement combination containing antioxidants (vitamins C, E, and beta-carotene), zinc, and copper could slow the progression of intermediate to late stage AMD.

The subsequent AREDS2 trial found that substituting beta-carotene for the antioxidants lutein and zeaxanthin improved the supplement’s efficacy and eliminated certain risks. At the time, neither trial detected any additional benefits after participants developed terminal disease.

However, this initial analysis did not take into account a phenomenon called “foveal sparing” in the dry form of late-stage AMD. Although all areas of the retina are sensitive to light, the area where central vision is most acute is called the fovea.

Many patients with atrophic AMD first develop geographic atrophy outside the foveal region, and only lose central vision when the area of ​​geographic atrophy spreads into the foveal region.

“Our high acuity central vision is essential for tasks such as reading and driving. Given that patients with end-stage dry AMD have few treatment options to preserve or restore vision, antioxidant supplementation is a simple step that may slow the decline of central vision, even in patients with end-stage disease,” Keenan said.

“We plan to confirm these results in a dedicated clinical trial in the near future.”

Funding:

Study authors include Keenan, Elvira Agrón and Emily Chew, MD, PhD, of NEI; Pearse Keane, MD, PhD, of Moorfields Eye Hospital in the UK; and Amitha Domalpally, MD, PhD, of the University of Wisconsin-Madison. This research was supported by the NEI Intramural Research Program.

Funding for the AREDS and AREDS2 studies was provided by the NEI and the NIH Office of Dietary Supplements, the National Center for Complementary and Alternative Medicine, the National Institute on Aging, the National Heart, Lung, and Blood Institute, and the National Institute of Neurological Disorders and Stroke under contract numbers NOI-EY-0-2127, HHS-N-260-2005-00007-C, and N01-EY-5-0007.

The AREDS and AREDS2 studies (clinicaltrials.gov numbers NCT00000145 and NCT00345176, respectively) were conducted at the NIH Clinical Center.

About this AMD and visual neuroscience research news

author: Leslie Earl
sauce: NIH (National Institutes of Health)
contact: Leslie Earl – NIH
image: Image courtesy of Neuroscience News

Original Research: Open access.
“Oral antioxidant and lutein/zeaxanthin supplements slow progression of geographic atrophy to the fovea in age-related macular degeneration” by Tiarnan Keenan et al. Ophthalmology


Abstract

Oral antioxidant and lutein/zeaxanthin supplements slow progression of geographic atrophy to the fovea in age-related macular degeneration

the purpose

To update the Age-Related Eye Disease Study (AREDS) Simplified Severity Scale for late-stage age-related macular degeneration (AMD) risk, including incorporation of reticular pseudosinuses (RPD), and to perform external validation in the Age-Related Eye Disease Study 2 (AREDS2).

design

Post hoc analysis of two clinical trial cohorts, AREDS and AREDS2.

participant

Participants were free of late AMD in both eyes at baseline in AREDS (n = 2719) and AREDS2 (n = 1472).

Method

Five-year progression rates to late AMD were calculated according to levels 0 to 4 of the Simplified Severity Scale after two updates. (1) Non-central geographic atrophy (GA) was considered part of the outcome rather than a risk characteristic, and (2) the scale was separated according to RPD status (determined by validated deep learning grading of color fundus photographs).

Main Evaluation Items

Five-year rate of progression to late AMD (defined as neovascular AMD or GA).

result

In AREDS, after the first scale update, the 5-year progression rates to late AMD for levels 0 to 4 were 0.3%, 4.5%, 12.9%, 32.2%, and 55.6%, respectively. For the final abbreviated severity scale, the 5-year progression rates for levels 0 to 4 in participants without RPD at baseline were 0.3%, 4.3%, 11.6%, 26.7%, and 50.0%, respectively, and for participants with RPD at baseline, the 5-year progression rates for levels 0 to 4 were 2.8%, 8.0%, 29.0%, 58.7%, and 72.2%, respectively. In external validation of AREDS2, progression rates from level 2 to 4 were similar: 15.0%, 27.7%, and 45.7% (without RPD) and 26.2%, 46.0%, and 73.0% (with RPD), respectively.

Conclusion

The AREDS AMD Simplified Severity Scale has been modernized with two important updates. For individuals without RPD, the 5-year progression rates of the new scale are approximately 0.5%, 4%, 12%, 25%, and 50%, maintaining the accuracy of the original scale. For individuals with RPD, the 5-year progression rates of the new scale are approximately 3%, 8%, 30%, 60%, and 70%, approximately double at most levels. The scale fits the updated definition of late AMD, improving prognostic accuracy and likely generalizing to similar populations, while remaining simple for broad risk classification.

Financial Disclosure

Any proprietary or commercial disclosures are set out in the footnotes and disclosures at the end of this article.

Age-related macular degeneration Aled Am AMD Antioxidants AREDS Brain Research dry LateStage loss Loss of vision Neurobiology Neuroscience NIH (National Institutes of Health) slow Supplement vision Visual Neuroscience
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
u1news-staff
u1news-staff
  • Website

Related Posts

America’s 10 priciest prescription medications by cost and by volume

May 13, 2025

FDA head raises alarm on ‘gas station heroin’ impact on youth

May 12, 2025

New AI tool analyzes face photos to predict health outcomes

May 12, 2025

Worst cities for allergies revealed, along with tips to manage symptoms

May 11, 2025
Add A Comment

Leave A Reply Cancel Reply

Latest Posts

America’s 10 priciest prescription medications by cost and by volume

May 13, 2025

FDA head raises alarm on ‘gas station heroin’ impact on youth

May 12, 2025

New AI tool analyzes face photos to predict health outcomes

May 12, 2025

Worst cities for allergies revealed, along with tips to manage symptoms

May 11, 2025
Unites States

Biden criticises ‘extreme’ Supreme Court in push for reform

July 30, 2024

FBI details shooter’s search history before Trump assassination attempt

July 30, 2024

Reps. Mike Kelly, Jason Crow to lead task force on Trump rally shooting

July 29, 2024

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Copyright ©️ All rights reserved. | U1 News
  • Home
  • About Us
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer

Type above and press Enter to search. Press Esc to cancel.